GLP-1 Weight Loss Drugs: 5 Things to Know BEFORE You Start
LISTEN ON APPLE PODCASTS | LISTEN ON SPOTIFY | LISTEN ON AMAZON MUSIC
There's a strange dynamic happening around GLP-1 medications right now. People who lost weight without them sometimes look down on people who use them — as if biology only counts if you suffered enough to earn it. Dr. Lara sees the other side of that daily: patients whose relationship with food changes completely once the constant mental noise around eating finally quiets down. Neither camp has the full picture. This episode is Dr. Lara's actual pre-prescribing conversation, condensed into five things worth understanding before you start.
A quick note before diving in: nothing here is medical advice. Talk to your own physician about your own situation.
Why this conversation matters right now
GLP-1 use has grown fast. Recent estimates put usage somewhere around 11% of U.S. adults, with as many as 15% having tried one at some point — a substantial jump from just a couple of years ago. Only two medications are currently FDA-approved specifically for weight loss, and more are in development, so this number isn't leveling off anytime soon.
Cost remains the biggest access barrier. Most patients are paying cash, since most insurance still doesn't cover these medications for weight loss specifically. Prices have come down somewhat, and Medicare recently launched limited coverage for patients who meet certain criteria — a meaningful shift that may eventually extend to other insurers.
Sourcing matters — compounded isn't automatically safe
Roughly one in five current GLP-1 users are on a compounded version rather than the FDA-approved brand-name medication. Compounding pharmacies mix their own formulations rather than sourcing from the original drug manufacturers, which means these versions haven't gone through the same safety review or research scrutiny as the approved medications.
Dr. Lara has seen patients start a compounded version on their own and notice no meaningful weight change — a signal that raises real questions about what's actually in the product. She's also had patients paying more for a compounded version than she could get them the FDA-approved medication for, which made switching an easy call. With compounded products, dosing standardization and quality control aren't guaranteed. If you go that route, it's genuinely at your own risk.
Know who shouldn't take these medications
The list of absolute contraindications is short. A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 rules it out — both rare conditions. Pregnancy and known hypersensitivity are also contraindications. If you've had gastroparesis or prior gastric surgery, extra caution applies, as it does if you're taking insulin or a sulfonylurea, since GLP-1s can compound their blood-sugar-lowering effect.
For the overwhelming majority of people, none of this applies. This is a short list, not a long one.
Side effects are usually manageable — and dosing should go slow
Most side effects are gastrointestinal: nausea, stomach discomfort, constipation, or diarrhea. For most patients, these are mild and improve within a few weeks as the body adjusts. Some people can't tolerate the medication at all, but that's the exception rather than the rule.
This is why dosing is titrated gradually, starting low and increasing month by month rather than jumping straight to a higher dose. Dr. Lara pushes back on a common practice she's seen elsewhere in the healthcare system: automatically doubling a patient's dose on schedule even when they're already losing weight steadily and feeling good at their current dose. The goal should be sustained, tolerable fat loss — not simply reaching the maximum studied dose because that's what the clinical trials targeted. Every dosing decision should be a conversation between patient and physician, not a default protocol.
Nutrition still isn't optional
This is the point David returns to repeatedly, because it's the one that gets missed most often. GLP-1s work by suppressing appetite, which makes a calorie deficit easier to sustain — but "I'm not hungry anymore" is not the same as "I don't need to eat well."
Dr. Lara talks nutrition with GLP-1 patients largely the same way she does with everyone else: keep eating regular meals throughout the day rather than skipping because you don't feel hungry, and prioritize protein intake specifically to protect muscle mass during weight loss. Some muscle loss accompanies any significant weight loss — this isn't unique to these medications, it happens with any effective weight-loss approach — but adequate protein and resistance training meaningfully shift the ratio toward fat loss rather than muscle loss. Skipping this piece because appetite suppression makes it easy to under-eat is one of the more common and avoidable mistakes patients make on these medications.
Being on a GLP-1 isn't weakness — it's biology, and it's a tool
The same people who happily discuss metabolic pathways, muscle protein synthesis, and macronutrient science tend to dismiss the biology of hunger and satiety as a character issue. That inconsistency is worth naming directly: ghrelin and leptin are real hormonal mechanisms, not moral failings.
Most patients who start a GLP-1 eventually ask about coming off it. That's a reasonable goal, but it comes with a caveat worth knowing upfront: research shows most people who discontinue these medications regain roughly two-thirds of the weight lost. Dr. Lara had a recent patient case that illustrates this directly — a patient stepped down his dose, gained weight back within a short window, and asked to return to his previous dose. These medications work by changing an active physiological process. When that process stops, the underlying biology it was managing typically returns.
Some patients will likely benefit from staying on a GLP-1 long-term, and that's not a problem to solve — it's appropriate, evidence-supported care for genuine physiological hunger dysregulation. Other patients may be able to use a GLP-1 as a bridge: enough time on the medication to build sustainable nutrition habits, after which the same behavioral changes — adequate protein, whole foods, addressing emotional eating patterns — can maintain results without ongoing medication. Distinguishing between these two situations isn't always straightforward, and it's exactly the kind of nuanced, individualized conversation a good primary care relationship is built for.
What's true either way: GLP-1s are a legitimate, well-supported tool. They're also not a complete substitute for the nutritional and behavioral foundation that determines long-term outcomes for everyone, medicated or not.
Vitals & Values is the podcast of Concierge Medicine of West Michigan, hosted by Dr. David Roden and Dr. Lara Baatenburg. New episodes available wherever you listen.
